Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03716531 | Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement(PACER) | active not recruiting | N/A | 199 | Massachusetts General HospitalOTHER |
| 1 |
| Jul 14, 2026 |
| clinicaltrials |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | active not recruiting | Phase 2 | 393 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07699757 | HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion | not yet recruiting | Phase 1 | 258 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07700992 | A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring(PANXEON) | recruiting | — | 600 | Università Vita-Salute San RaffaeleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07703813 | Energy Expenditure and Nutrition After Pancreatic Surgery(NUTRI-PD) | recruiting | — | 150 | Evangelismos HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05277766 | Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer(PIPAC-NAL-IRI) | active not recruiting | Phase 1 | 45 | University Hospital, GhentOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04233866 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | active not recruiting | Phase 2 | 176 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05355298 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 62 | Amplia Therapeutics LimitedINDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05411094 | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors(AMPLIFY-7P) | active not recruiting | Phase 1 / Phase 2 | 158 | Elicio TherapeuticsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT07436741 | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer | recruiting | Phase 3 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | active not recruiting | Phase 2 | 24 | Bruno BockornyOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06282809 | The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy(GANNON) | recruiting | N/A | 50 | HistoSonics, Inc.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07243262 | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) | recruiting | — | 6,079 | Imperial College LondonOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07612046 | A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening | recruiting | — | 79 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691593 | Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer | not yet recruiting | Phase 2 | 60 | Changhai HospitalOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07692750 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 56 | Zhejiang Cancer HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06981273 | Robotic vs Open Pancreatoduodenectomy(SPAIN PD) | recruiting | N/A | 120 | Hospital del MarOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689539 | Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 3 | 360 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07689955 | A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer(PANCPLEX) | not yet recruiting | Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07224750 | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer(MiGIC) | recruiting | — | 1,000 | City of Hope Medical CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04477343 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | Phase 1 | 20 | University of RochesterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06435260 | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer | recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | recruiting | Phase 1 | 210 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT07481383 | A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer | recruiting | Phase 1 | 12 | Continuity Biosciences, LLCINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683221 | SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 47 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683845 | Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer | recruiting | — | 164 | Beijing Daxiang Biotech Co., LtdINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04427761 | A Study of the Life Changes Experienced by Patients With Pancreatic Cancer | active not recruiting | — | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06001268 | Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)(STRONG-PCS) | active not recruiting | N/A | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07561814 | A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data | recruiting | — | 1,030 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study(INSPIRE) | not yet recruiting | N/A | 2,748 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04098081 | 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 15 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07022015 | Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy(POPF) | recruiting | N/A | 100 | Minia UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07186296 | EXoPERT EMERALD Clinical Study | recruiting | — | 1,400 | EXoPERTINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05013216 | Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer | recruiting | Phase 1 | 37 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06015724 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer(DARANIVOVAX) | active not recruiting | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07458347 | A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation | recruiting | Phase 1 | 145 | Kestrel Therapeutics, Inc.OTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07529626 | Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer(MIND-PANC) | recruiting | — | 320 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03851133 | Florida Pancreas Collaborative Next Generation Biobank | active not recruiting | — | 500 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07122466 | Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy | active not recruiting | — | 24 | Northwell HealthOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07605819 | Pancreatic Cancer Screening Using the Enzeavour Assay in Japan(ENZEAVOUR FS) | recruiting | N/A | 10,000 | Cosomil, Inc.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 15, 2026source: clinicaltrials